346 related articles for article (PubMed ID: 34706967)
1. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
4. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
5. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
6. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
7. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
8. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study.
Bertrand D; Matignon M; Morel A; Ludivine L; Lemoine M; Hanoy M; Roy FL; Nezam D; Hamzaoui M; de Nattes T; Moktefi A; François A; Laurent C; Etienne I; Guerrot D
Nephrol Dial Transplant; 2023 Feb; 38(2):481-490. PubMed ID: 35544123
[TBL] [Abstract][Full Text] [Related]
9. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
[TBL] [Abstract][Full Text] [Related]
10. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
[TBL] [Abstract][Full Text] [Related]
11. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
13. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
14. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
[TBL] [Abstract][Full Text] [Related]
15. Conversion to belatacept after lung transplantation: Report of 10 cases.
Brugière O; Vallée A; Raimbourg Q; Peraldi MN; de Verdière SC; Beaumont L; Hamid A; Zrounba M; Roux A; Picard C; Parquin F; Glorion M; Oniszczuk J; Hertig A; Mal H; Bunel V
PLoS One; 2023; 18(3):e0281492. PubMed ID: 36920935
[TBL] [Abstract][Full Text] [Related]
16. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
[TBL] [Abstract][Full Text] [Related]
17. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
18. Conversion to Belatacept in kidney transplant recipients with chronic antibody-mediated rejection (CAMR).
Moein M; Gao SX; Martin SJ; Farkouh KM; Li BW; Ball AS; Dvorai RH; Saidi RF
Transpl Immunol; 2023 Feb; 76():101737. PubMed ID: 36379374
[TBL] [Abstract][Full Text] [Related]
19. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
[TBL] [Abstract][Full Text] [Related]
20. Three-Year Outcomes in Kidney Transplant Recipients Switched From Calcineurin Inhibitor-Based Regimens to Belatacept as a Rescue Therapy.
Morel A; Hoisnard L; Dudreuilh C; Moktefi A; Kheav D; Pimentel A; Sakhi H; Mokrani D; Attias P; El Sakhawi K; Champy CM; Remy P; Sbidian E; Grimbert P; Matignon M
Transpl Int; 2022; 35():10228. PubMed ID: 35497889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
